A novel series of histamine H4 receptor antagonists based on the pyrido[3,2-d]pyrimidine scaffold: Comparison of hERG binding and target residence time with PF-3893787

https://doi.org/10.1016/j.bmcl.2013.02.091Get rights and content

Abstract

In this work we describe the optimization of a lead compound based on the quinazoline template to give a new series of potent pyrido[3,2-d]pyrimidines as histamine H4 receptor antagonists. The pyrido[3,2-d]pyrimidine ligands have significantly reduced hERG binding compared to clinical stage compound PF-3893787 while showing good affinities at the human and rodent histamine receptors. The receptor residence time of several of these new compounds was determined for the human H4R and compared with JNJ7777120 and PF-3893787. The pyrido[3,2-d]pyrimidines showed residence times lower than JNJ7777120 but comparable to the residence time of PF-3893787. Overall, the pyrido[3,2-d]pyrimidines show an excellent in vitro profile that warrants their further investigation in relevant models of human disease.

Section snippets

Acknowledgments

The authors would like to thank Maikel Wijtmans, Andreas Ehlers, Hans Custers and Andrea van de Stolpe for their unrelenting support and fruitful discussions. This work was supported by COST action BM0806.

References and notes (20)

  • P.J. Dunford et al.

    J. Allergy Clin. Immunol.

    (2007)
  • R.A. Smits et al.

    Bioorg. Med. Chem. Lett.

    (2012)
  • C.E. Mowbray et al.

    Bioorg. Med. Chem. Lett.

    (2011)
  • Lim, H. D. Ligand-Receptor Interactions of the Histamine H4 Receptor, Doctoral Thesis, VU University Amsterdam, The...
  • C.L. Hofstra et al.

    J. Pharm. Exp. Ther.

    (2003)
  • R.L. Thurmond et al.

    Nat. Rev. Drug Disc.

    (2008)
  • R.A. Smits et al.

    Drug Discov. Today

    (2009)
  • R. Gutzmer et al.

    Front. Biosci. (Schol Ed.)

    (2011)
  • G. Desmadryl et al.

    Br. J. Pharmacol.

    (2012)
  • D.G. Shagufta et al.

    ChemMedChem

    (2009)
There are more references available in the full text version of this article.

Cited by (25)

  • Bicyclic 6-6 Systems: Three Heteroatoms 1:2

    2021, Comprehensive Heterocyclic Chemistry IV
  • BRET-based β-arrestin2 recruitment to the histamine H<inf>1</inf> receptor for investigating antihistamine binding kinetics

    2016, Pharmacological Research
    Citation Excerpt :

    The maximal β-arrestin2 recruitment was diminished upon pre-treatment with PBZ in a concentration-dependent manner, whereas the potency of histamine to recruit β-arrestin2 was unaffected (Table 1). Ligand binding kinetics of the unlabeled antihistamines are typically measured in competition with a radioligand [17,19,20,35,36]. However, the prognostic value might be higher when this is measured from the functional response using a real-time assay on living cells in competition with the endogenous agonist.

  • Recent advances in the chemistry and biology of pyridopyrimidines

    2015, European Journal of Medicinal Chemistry
    Citation Excerpt :

    Antagonists are considered as potential drugs for the treatment of allergic asthma. Smits et al. described the synthesis of the pyrido[2,3-d] pyrimidine ligand as a histamine H4 receptor antagonist to reduce hERG binding, with good affinities to the human and rodent histamine receptor H4R [48]. The chiral derivative 142 was prepared from the 4-chloro-7-bromoderivative 141 by substitution of the 4-chloro atom which allowed the introduction of the (R)-3-Bocaminopyrolidine substituent.

  • H<inf>4</inf> receptor antagonists and their potential therapeutic applications

    2014, Annual Reports in Medicinal Chemistry
    Citation Excerpt :

    Despite this favorable profile, 25 had three major issues: (1) high hERG binding, (2) metabolically labile N-methyl piperazine, (3) the furan group was associated with undesired metabolic activation and covalent binding to proteins. These issues were resolved by the introduction of an additional nitrogen to the quinazoline to form a pyrido[3,2-d]pyrimidine, replacement of the N-methylpiperazine with 3-methylamino azetidine, and replacement of the tetrahydrofuran group with an alkyl or cycloalkyl group to afford compounds such as 26.41 It was found that the hERG binding was significantly reduced while maintaining good affinities to both human and rodent histamine receptors, with a fourfold higher residence time in the hH4 receptor in comparison to 25.

View all citing articles on Scopus
View full text